YEAR: 2011
Evidence Based Medicine in Schizophrenia W8
21-25 February 2011, Copenhagen
Evidence Based Medicine in Mood Disorders W6
7-11 February 2011, Copenhagen
Evidence Based Medicine in Dementia and Old Age Depression W13
28 March -1 April 2011, Copenhagen
Faculty Update Meeting VI: "Are current treatment options effective in shaping patient outcomes in schizophrenia?"
25 March 2011, Rome
e-learning based on the Faculty Update Meeting VI: "Are current treatment options effective in shaping patient outcomes in schizophrenia?"
25 March 2011, Rome
4th World Congress on Women's Mental Health
16-19 March 2011, Madrid
"Addressing the challenge of optimising treatment in major depressive disorder", a satellite symposium on the occasion of the 19th EPA European Congress of Psychiatry with educational financial support provided by AstraZeneca
15 March 2011, Vienna
"Depression: from early intervention to long term outcome" a Satellite symposium on the occasion of the 19th EPA European Congress of Psychiatry with educational financial support provided by Eli Lilly and Company
13 March 2011, Vienna
"Treating the symptomatic burden of bipolar depression and major depressive disorder" a Satellite symposium on the occasion of the 19th EPA European Congress of Psychiatry with educational financial support provided by AstraZeneca
13 March 2011, Vienna
11th ECNP Regional Meeting
14-16 April 2011, St Petersburg
The Lundbeck Symposium - Focus on CNS disorders 2011
Session 4 "Addressing clinical progression in Alzheimer's disease"
10 April 2011, Athens
The Symposium - Focus on CNS disorders 2011
Session 5 "Molecular and clinical prodromes and progression of Parkinson's disease: implications for treatment"
10 April 2011, Athens
3rd Scientific symposium on Niemann-Pick Type C: Progressing from research to clinical benefit, with educational financial support provided by Actelion
9-10 April 2011, Prague
The Lundbeck Symposium - Focus on CNS disorders 2011
Session 1 "The impact of symptom control and long-term tolerability"
9 April 2011, Athens
The Lundbeck Symposium - Focus on CNS disorders 2011
Session 2 "A consultation with the Depression Expert Committee"
9 April 2011, Athens
The Lundbeck Symposium - Focus on CNS disorders 2011
Session 3 "Towards new treatment approaches for depression and for alcohol dependence"
9 April 2011, Athens
"Reaching beyond partial response in depression" a Satellite symposium on the occasion of the CINP Congress
2 April 2011, Salzburg
"ADHD in adolescents: prognosis, functional outcomes and improving adherence" standalone sponsored by Janssen Pharmaceutica
27 May 2011, Berlin
Standalone "Clinics on Parkinson's disease, restless syndrome and narcolepsy" sponsored by UCB
13-14 May 2011, Mälmo
Regional Informational Conference for the Mood Disorders, sponsored by Eli Lilly Regional Operations Ges.m.b.H
5-6 May 2011, Madrid
Evidence Based Medicine in Anxiety Disorders W18
2-6 May 2011, Copenhagen
e-learning based on the ADHES Educational Meeting:"The adherence challenge in schizophrenia: an update of the ADHES initiative"
20 June 2011, Berlin
ADHES Educational Meeting:"The adherence challenge in schizophrenia: an update of the ADHES initiative"
10-11 June 2011, Berlin
Evidence-based Medicine in Dementia and Old Age Depression W23
6-10 June 2011, Copenhagen
ICAD/AICC symposium: "Amyloid-Related Imaging Abnormalities in Amyloid-Modifying Therapy Research" presented by the Alzheimer's Immunotherapy Programme
20 July 2011, Paris
Summer Course on Mood Disorders
3-8 July 2011, Florence
ECNP School of Neuropsychopharmacology
3-8 July 2011, Oxford
ICAD/AICC symposium: Amyloid-Related Imaging Abnormalities in Amyloid-Modifying Therapy Research presented by the Alzheimer's Immunotherapy Programme
20-Jul-11, Paris
1st Alpine Sleep Summer School (ASSS) an introductory course in Sleep Medicine
22-27 August 2011, Lugano
22nd EUNETHYDIS Meeting: the next 10 years
29 September - 2nd October 2011, Budapest
Evidence-based Medicine in Dementia and Old Age Depression W39
26-30 September 2011, Copenhagen
"Pain in Diabetic Neuropathy: New Insights into the mechanisms and Treatment Guidelines" Satellite symposium at the EFIC Congress with educational financial support provided by Eli Lilly and Company
23 September 2011, Hamburg
"Treating depression: current antidepressants and beyond" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Servier
6 September 2011, Paris
"Glutamate, glycine and schizophrenia: a promising therapeutic approach" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Roche
6 September 2011, Paris
"Opportunities and challenges in the management of patients with major depressive disorder" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by AstraZeneca
6 September 2011, Paris
"Bipolar disorder: Shifting paradigm" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by FondaMental Foundation Symposium
6 September 2011, Paris
"Circadian abnormalities in the continuum of mood disorders" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Servier
5 September 2011, Paris
"Understanding the complex interactions in GAD: from the laboratory to the clinic" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Pfizer Ltd
5 September 2011, Paris
"Effective long-term treatment of schizophrenia: are we there yet?" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Janssen Pharmaceutical Companies of Johnson and Johnson
5 September 2011, Paris
"Relationship between aesthetics and treatment success in depression" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by H. Lundbeck A/S
5 September 2011, Paris
Live broadcast based on the "Effective long-term treatment of schizophrenia: are we there yet?" Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Janssen Pharmaceutical Companies of Johnson and Johnson
5 September 2011, Paris
e-learning based on the "Effective long-term treatment of schizophrenia: are we there yet?" Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Janssen Pharmaceutical Companies of Johnson and Johnson
5 September 2011, Paris
"Clinical controversies and realities of treating bipolar mania patients" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Bristol-Myers Squibb Pharmaceutical Ltd and Otsuka Pharmaceutical Europe Ltd
4 September 2011, Paris
"Long-term treatment outcomes in schizophrenia: new hopes for a new decade?" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Eli Lilly and Company
4 September 2011, Paris
"Difficult to diagnose psychoses: the case for organic causes of disease" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Actelion Pharmaceuticals Ltd
4 September 2011, Paris
"Depressive symptoms: a common challenge in psychiatric disorders?" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by AstraZeneca
4 September 2011, Paris
24th ECNP Congress, 3-7 September 2011, Paris, France
3-7 September 2011, Paris
"Are we doing enough to increase treatment success rates in depression and anxiety?" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by H. Lundbeck A/S
3 September 2011, Paris
"What neurobiology and patients tell us about intervention strategies in major depressive disorder?" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Eli Lilly and Company
3 September 2011, Paris
"Meaningful remission - the future objective in treating bipolar I disorder" a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by H. Lundbeck A/S
3 September 2011, Paris
Are we doing enough to increase treatment success rates in depression and anxiety? a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by H. Lundbeck A/S
03-Sep-11, Paris
Treating depression: current antidepressants and beyond a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Servier
06-Sep-11, Paris
Circadian abnormalities in the continuum of mood disorders a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Servier
05-Sep-11, Paris
What neurobiology and patients tell us about intervention strategies in major depressive disorder? a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Eli Lilly and Company
03-Sep-11, Paris
Meaningful remission - the future objective in treating bipolar I disorder a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by H. Lundbeck A/S
03-Sep-11, Paris
Clinical controversies and realities of treating bipolar mania patients a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Bristol-Myers Squibb Pharmaceutical Ltd and Otsuka Pharmaceutical Europe Ltd
04-Sep-11, Paris
Long-term treatment outcomes in schizophrenia: new hopes for a new decade? a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Eli Lilly and Company
04-Sep-11, Paris
Difficult to diagnose psychoses: the case for organic causes of disease a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Actelion Pharmaceuticals Ltd
04-Sep-11, Paris
Depressive symptoms: a common challenge in psychiatric disorders? a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by AstraZeneca
04-Sep-11, Paris
Understanding the complex interactions in GAD: from the laboratory to the clinic a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Pfizer Ltd
05-Sep-11, Paris
Effective long-term treatment of schizophrenia: are we there yet? a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Janssen Pharmaceutical Companies of Johnson and Johnson
05-Sep-11, Paris
Relationship between aesthetics and treatment success in depression a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by H. Lundbeck A/S
05-Sep-11, Paris
Glutamate, glycine and schizophrenia: a promising therapeutic approach a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Roche
06-Sep-11, Paris
Opportunities and challenges in the management of patients with major depressive disorder a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by AstraZeneca
06-Sep-11, Paris
Bipolar disorder: Shifting paradigm a Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by FondaMental Foundation Symposium
06-Sep-11, Paris
Live broadcast based on the Effective long-term treatment of schizophrenia: are we there yet? Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Janssen Pharmaceutical Companies of Johnson and Johnson
05-Sep-11, Paris
24th ECNP Congress, 3-7 September 2011, Paris, France
3-7 September 2011, Paris
e-learning based on the Effective long-term treatment of schizophrenia: are we there yet? Satellite symposium on the occasion of the 24th ECNP Congress with educational financial support provided by Janssen Pharmaceutical Companies of Johnson and Johnson
05-Sep-11, Paris
MED Ψ Forum, 2nd Session, Cascais, 26-29 October 2011
26-29 October 2011, Cascais
Evidence Based Medicine in Mood Disorders W43
24-28 October 2011, Copenhagen
Medical Education Standalone Meeting "The shape of the future - is living a normal life a possibility for our patients with schizophrenia?"
14-15 October 2011, Madrid
Live broadcast based on the Medical Education Standalone Meeting "The shape of the future - is living a normal life a possibility for our patients with schizophrenia?"
14-15 October 2011, Madrid
Live webcast based on the Medical Education Standalone Meeting "The shape of the future - is living a normal life a possibility for our patients with schizophrenia?"
14-15 October 2011, Madrid
RIC "Current Treatments and Future Strategies for Diabetic Peripheral Neuropathic Pain"
13-14 October 2011, Vienna
Evidence Based Medicine in Anxiety Disorders W41
10-14 October 2011, Copenhagen
II International Congress on Dual Disorders Addictive Behaviors and Other Mental Disorders
5th-8th October 2011, Barcelona
Masterclass: "The Five Ages of Epilepsy"
18-19 November 2011, Salzburg
Expert Meeting "Asenapine: an untypical antipsychotic for the treatment of bipolar disorder"
18 November 2011, Amsterdam
MDD Scientific Exchange Meeting "Diagnosing and Managing Depression in Diverse Presentations" group A
17-18 November 2011, Brussels
MDD Scientific Exchange Meeting "Diagnosing and Managing Depression in Diverse Presentations" group B
17-18 November 2011, Brussels
Schizophrenia Scientific Exchange Meeting: "New Treatment, New Perspectives"
10-11 November 2011, Lisbon
Evidence-based Medicine in Dementia and Old Age Depression
7-11 November 2011, Copenhagen
International Sleep Medicine Course
7-10 November 2011, Sint Michielsgestel
1st International Movement & Sleep Disorders Summit
1-3 December 2011, Marseille